This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-25. Anything still debated is marked as such rather than presented as settled.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
In 1967, Hood joined the National Institutes of Health (NIH), to work in the immunology branch of the National Cancer Institute as a senior investigator. In 1970, he returned to Caltech as an assistant professor. He was promoted to associate professor in 1973, full professor in 1975, and was named Bowles Professor of Biology in 1977. He served as chairman of the Division of Biology from 1980-1989 and director of Caltech's Special Cancer Center in 1981. Hood has been a leader and a proponent of cross-disciplinary research in chemistry and biology. In 1989 he stepped down as chairman of the Division of Biology to create and become director of a newly funded NSF Science and Technology Center at Caltech. The NSF Center for the Development of an Integrated Protein and Nucleic Acid Biotechnology became one of the founding research centers of the Beckman Institute at Caltech in 1989. By this time, Hood's laboratory included more than 100 researchers, a much larger group than was usual at Caltech. A relatively small school, Caltech was not well-suited to the creation of the type of large interdisciplinary research organization that Hood sought. In October 1991, Hood announced that he would move to the University of Washington at Seattle, to found and direct the first cross-disciplinary biology department, the Department of Molecular Biotechnology (MBT) at the University of Washington Medical School.
This continuous process is highly efficient for producing large volumes of coated materials, which are essential in various industries including printing, packaging, and electronics. The technology allows for consistent high-quality application of the coating material over large surface areas, enhancing productivity and uniformity.
==== Waterboarding ==== Hitchens was asked by Vanity Fair to experience waterboarding for himself at a U.S. Army training facility. In May 2008, Hitchens voluntarily underwent the procedure. Hitchens stopped the procedure after 11 seconds and subsequently endorsed the view that it was "torture." He concluded, "If waterboarding does not constitute torture, then there is no such thing as torture."
Sources: en.wikipedia.org
Meanwhile, the Prince and Princess of Wales release a monochrome photograph of them and their children: Prince George of Wales, Princess Charlotte of Wales, and Prince Louis of Wales. 10 December Lawyers on the right of the Conservative Party describe the new Rwanda legislation as not "sufficiently watertight". In his first broadcast since leaving the post of Immigration Minister, Robert Jenrick tells the BBC Sunak's draft Rwanda law unlikely to work since it is "weak" and will become "bogged down" in legal challenges. The skull of a pliosaur is discovered off the coast of Dorset. The 2 m (6 ft 7 in) fossil is said to have roamed the waters 150 million years ago. A David Attenborough documentary is scheduled to air on BBC One on New Year's Day revealing the "risky mission" of unearthing the "T-Rex of the seas". 11 December The National Crime Agency (NCA) suggests that street drugs stronger than heroin are linked to the deaths of at least 54 people in the past six months, with 40 more cases awaiting further testing. The UK government is offering a £2.5bn financial package for the return of a Stormont Executive, which includes funds to settle public sector disputes and for public services. 12 December The UK government's Safety of Rwanda (Asylum and Immigration) Bill, a piece of emergency legislation to support the Rwanda asylum plan, passes with a majority of 44 as MPs vote 313–269 in favour of it. Dorset Police are investigating following the death of an asylum seeker, thought to have taken his own life, on the accommodation barge Bibby Stockholm.
== Areas of application and limits == First used in theoretical physics, the molecular dynamics method gained popularity in materials science soon afterward, and since the 1970s it has also been commonly used in biochemistry and biophysics. MD is frequently used to refine 3-dimensional structures of proteins and other macromolecules based on experimental constraints from X-ray crystallography or NMR spectroscopy. In physics, MD is used to examine the dynamics of atomic-level phenomena that cannot be observed directly, such as thin film growth and ion subplantation, and to examine the physical properties of nanotechnological devices that have not or cannot yet be created. In biophysics and structural biology, the method is frequently applied to study the motions of macromolecules such as proteins and nucleic acids, which can be useful for interpreting the results of certain biophysical experiments and for modeling interactions with other molecules, as in ligand docking. In principle, MD can be used for ab initio prediction of protein structure by simulating folding of the polypeptide chain from a random coil. MD can also be used to compute other thermodynamic properties such as drug solubilities and free energies of solvation including in polymers. The results of MD simulations can be tested through comparison to experiments that measure molecular dynamics, of which a popular method is NMR spectroscopy.
=== EC 1.3.7 With an iron–sulfur protein as acceptor === EC 1.3.7.1: 6-hydroxynicotinate reductase EC 1.3.7.2: 15,16-dihydrobiliverdin:ferredoxin oxidoreductase EC 1.3.7.3: phycoerythrobilin:ferredoxin oxidoreductase EC 1.3.7.4: phytochromobilin:ferredoxin oxidoreductase EC 1.3.7.5: phycocyanobilin:ferredoxin oxidoreductase EC 1.3.7.6: phycoerythrobilin synthase EC 1.3.7.7: ferredoxin:protochlorophyllide reductase (ATP-dependent) EC 1.3.7.8: benzoyl-CoA reductase EC 1.3.7.9: 4-hydroxybenzoyl-CoA reductase EC 1.3.7.10: pentalenolactone synthase EC 1.3.7.15: chlorophyllide a reductase
Sources: en.wikipedia.org
== Culture == Most of the district's news media has been either weekly or monthly publications. The earliest newspaper was the Scarborough News and Advertiser which was published weekly starting in September 1921, which lasted until the 1930s. Other short-lived papers and magazines included The Enterprise (1945–1966), Scarborough Mail (1946–1955) and The News (1952–1996) and 54east magazine (2005–2009). The last remaining English-language local newspaper was the Scarborough Mirror, which started publication in 1962 and was later acquired by the Toronto Star's community news division, Metroland. In 2023, it became an online-only publication as part of Toronto.com. A Scarborough edition of the Toronto-wide photography publication SNAP Scarborough was launched in 2009. Ming Pao Daily News is a Chinese-language newspaper whose headquarters is in the district. They started publication in 1993. In 1961, the CTV Toronto (CFTO) television channel began operating from the 9 Channel Nine Court studios at the intersection of McCowan Road and Highway 401. Today, the studio also is the headquarters of The Sports Network (TSN). Both companies produce programming at the studio. In 1970, Trillium Cable started to provide cable TV service to Scarborough. It was purchased by Shaw Cable in 1995; but later swapped with Rogers Cable in 2001. During the early days of the company, they produced several local shows for their own cable channel. These shows were produced by volunteers and showed a wide variation in quality. These shows were satirized by Mike Myers in his comedy film Wayne's World.
=== Features that promote de novo gene birth === Its also of interest to compare features of recently emerged de novo genes to the pool of non-genic ORFs from which they emerge. Theoretical modeling has shown that such differences are the product both of selection for features that increase the likelihood of functionalization, and of neutral evolutionary forces that influence allelic turnover. In budding yeast, systematic deletion and overexpression assays of newly emerged ORFs found that overexpression is enriched for fitness benefits, and that adaptive emerging sequences are biased toward encoding transmembrane domains from thymine-rich intergenic regions. One proposed route to de novo membrane proteins is that poly-A–rich sequences can generate hydrophobic ORFs that are predicted to form transmembrane helices. Across Saccharomycotina yeasts, intergenic regions show widespread enrichment for putative transmembrane-domain encoding potential, and this enrichment (rather than raw hydrophobicity alone) correlates with the abundance of transmembrane domains in evolutionarily young genes. Laboratory studies comparing young de novo proteins to matched unevolved random-sequence proteins found broadly similar predicted biophysical-property distributions, but moderately higher in vitro solubility for de novo proteins (further increased by the DnaK chaperone system). High-throughput sorting of thousands of putative human de novo sORF-encoded proteins by structural compactness showed that older candidates are, on average, more compact and less disordered than younger ones.
As a mucous connective tissue, it is rich in proteoglycans, and protects and insulates umbilical blood vessels. Wharton's jelly, when exposed to temperature changes, collapses structures within the umbilical cord and thus provides a physiological clamping of the cord, typically three minutes after birth.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.